Market attention on Genomictree is focused on the progress of commercializing its early cancer detection products.

A key medium- to long-term watch point is that EarlyTect-B, aimed at bladder cancer diagnosis, and EarlyTect-C, an early colorectal cancer detection product, are being commercialized at different stages.

In this regard, a report on Genomictree released by Korea Investment & Securities on July 28 is drawing renewed attention. However, it should be noted that this is not a new report as of the current date, but a past report published last month.

At the time, Korea Investment & Securities published a report titled "Two Is Better Than One After All." In the report, the firm analyzed Genomictree's product pipeline on the premise that cancer is more favorable to treat when detected early.

In particular, it highlighted both EarlyTect-B, which is scheduled for non-reimbursed sales in the second half of the year, and EarlyTect-C, which is being discussed as a candidate for reimbursement momentum in 2027.

The core point is that the company's structure does not rely on a single product; rather, commercialization schedules for diagnostic products targeting different cancer types are continuing in succession.

[This article was written with the assistance of AI. It is not intended to solicit investment, and investment decisions and any resulting responsibility rest solely with the investor.]